Cargando…

The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19

The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality on a global scale. The etiologic agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), initiates host cell entry when its spike protein (S) binds to its receptor, angiotensin-converting enz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Kun, Meyerholz, David K., Bartlett, Jennifer A., McCray, Paul B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406266/ https://www.ncbi.nlm.nih.gov/pubmed/34340553 http://dx.doi.org/10.1128/mBio.00970-21

Ejemplares similares

Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
por: Hempel, Tim, et al.
Publicado: (2020)

Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
por: Neary, Megan, et al.
Publicado: (2023)

Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2
por: Zhu, Haixia, et al.
Publicado: (2020)

RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia
por: Seccia, Teresa Maria, et al.
Publicado: (2023)

Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations
por: Ramakrishnan, Jaganathan, et al.
Publicado: (2021)

Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach
por: Sonawane, Kailas D., et al.
Publicado: (2021)

RNA G-quadruplex in TMPRSS2 reduces SARS-CoV-2 infection
por: Liu, Geng, et al.
Publicado: (2022)

Targeting TMPRSS2 in SARS-CoV-2 Infection
por: Baughn, Linda B., et al.
Publicado: (2020)

In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity
por: Fujimoto, Kazuhiro J., et al.
Publicado: (2022)

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2
por: Azouz, Nurit P., et al.
Publicado: (2020)

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2–Priming Protease TMPRSS2
por: Azouz, Nurit P., et al.
Publicado: (2021)

Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture
por: Wettstein, Lukas, et al.
Publicado: (2022)

TMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein
por: Kishimoto, Mai, et al.
Publicado: (2021)

The first few days of a SARS-CoV-2 infection viewed at single-cell resolution
por: Gallagher, Tom, et al.
Publicado: (2021)

Increased susceptibility to otitis media in a Splunc1-deficient mouse model
por: Bartlett, Jennifer A., et al.
Publicado: (2015)

Schizophyllum commune Reduces Expression of the SARS-CoV-2 Receptors ACE2 and TMPRSS2
por: Sun, Te-Kai, et al.
Publicado: (2022)

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
por: Zang, Ruochen, et al.
Publicado: (2020)

Inter-individual Variation in Receptor Expression Influences MERS-CoV Infection and Immune Responses in Airway Epithelia
por: Li, Kun, et al.
Publicado: (2022)

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
por: Hoffmann, Markus, et al.
Publicado: (2020)

A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
por: Shapira, Tirosh, et al.
Publicado: (2022)

Antiandrogens Target TMPRSS2 and Reduce SARS-CoV-2 Virus Entry in Lung Cells
por: Leach, Damien A, et al.
Publicado: (2021)

TMPRSS2 and SARS-CoV-2 SPIKE interaction assay for uHTS
por: Cicka, Danielle, et al.
Publicado: (2023)

Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease
por: Stevaert, Annelies, et al.
Publicado: (2022)

Exploring the phytochemicals of Platycodon grandiflorus for TMPRSS2 inhibition in the search for SARS-CoV-2 entry inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2022)

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
por: Matsuyama, Shutoku, et al.
Publicado: (2020)

Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity
por: Essalmani, Rachid, et al.
Publicado: (2022)

Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin
por: Ohradanova-Repic, Anna, et al.
Publicado: (2022)

TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection
por: Metzdorf, Kristin, et al.
Publicado: (2023)

Illuminating COVID-19 lung disease through autopsy studies
por: Meyerholz, David K., et al.
Publicado: (2020)

SARS-CoV2, the COVID-19 Pandemic and Community Perceptions
por: Keene Woods, Nikki, et al.
Publicado: (2021)

The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
por: Leach, D. A., et al.
Publicado: (2021)

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
por: Ou, Tianling, et al.
Publicado: (2021)

Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways
por: Iwata-Yoshikawa, Naoko, et al.
Publicado: (2022)

In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2)
por: Barge, Sagar, et al.
Publicado: (2021)

SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection
por: Li, Kun, et al.
Publicado: (2020)

Sensitization of Non-permissive Laboratory Mice to SARS-CoV-2 with a Replication-Deficient Adenovirus Expressing Human ACE2
por: Wong, Lok-Yin Roy, et al.
Publicado: (2020)

Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection
por: Maggio, Roberto, et al.
Publicado: (2020)

BC‐11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS‐CoV‐2 host cell entry
por: Moumbock, Aurélien F. A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s7esdeujhcngssf3555e4pohr8